Cite
HARVARD Citation
Naqvi, K. et al. (2018). Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer. 124 (13), pp. 2740-2747. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Naqvi, K. et al. (2018). Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer. 124 (13), pp. 2740-2747. [Online].